Abstract
To evaluate the efficacy of sulfasalazine (SSZ) for recurrent acute anterior uveitis (AAU). Retrospectivechartreview ofpatientsdiagnosed withrecurrent AAU treated with SSZfromJanuary2008 toSeptember 2023. Thegrading ofuveitisactivitywasdefined asper SUNworkinggroup. The primary outcome was thereductionin thenumber ofuveitisflare-upsover a one-year, two-year and three year-period,comparedto pre-treatment year.The response criteriato SSZwere defined as normal ophthalmologic examination. Paired samples Wilcoxon test and Kaplan-Meiersurvival curvewerecalculated using R-Commander statistical software (p < 0.05). Fifty-three patients were included. Mean time of follow up was 38.51 ± 38.45months.Nine patients developed adverse effects to SSZ (16.98%) most of them mild. Ankylosingspondylitis was the most frequent association(n = 28,52.83%), while HLA-B27 was positive in 69.23% of the patients (n = 36). The most frequent indication for SSZ was based on ocular activity in 52.83% (n = 28). The number of flare-ups dropped from 2.25 (± 1.34) in the pre-treatment year to, 0.81(± 0.99) at year 1 (p < 0.001), 0.61 (± 0.78) at year 2 (p < 0.001) and 0.65 (± 0.83) at year 3 (p = 0.005).The median time to flare-upof AAUafter SSZwas15.13months(CI 95, 7.97-27.40). Our data point to sulfasalazine as an effective treatmentto reduce flare-upsin patients with recurrentnon-infectious AAU.Itslow cost andgoodsafetyprofilemake it an interestingtherapeuticalternative,especially in women of childbearing age.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call